Plasmid DNA Manufacturing Market (By Product: Viral Vectors, Plasmid DNA, Non-Viral, Electroporation, Lipid/Polymer, Nanoparticles, and Others; By Application: Gene Therapy, DNA Vaccines, Immunotherapy, Others; By Disease: Infectious Disease, Genetic Disorder, and Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2021 - 2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Plasmid DNA Manufacturing Market, By Product

7.1. Plasmid DNA Manufacturing Market, by Product Type, 2021-2030

7.1.1. Viral Vectors

7.1.1.1. Market Revenue and Forecast (2019-2030)

7.1.2. Plasmid DNA

7.1.2.1. Market Revenue and Forecast (2019-2030)

7.1.3. Non-Viral

7.1.3.1. Market Revenue and Forecast (2019-2030)

7.1.4. Electroporation

7.1.4.1. Market Revenue and Forecast (2019-2030)

7.1.5. Lipid/Polymer

7.1.5.1. Market Revenue and Forecast (2019-2030)

7.1.6. Nanoparticles

7.1.6.1. Market Revenue and Forecast (2019-2030)

7.1.7. Others

7.1.7.1. Market Revenue and Forecast (2019-2030)

Chapter 8. Global Plasmid DNA Manufacturing Market, By Application

8.1. Plasmid DNA Manufacturing Market, by Application, 2021-2030

8.1.1. Gene Therapy

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Immunotherapy

8.1.2.1. Market Revenue and Forecast (2019-2030)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Plasmid DNA Manufacturing Market, By Disease 

9.1. Plasmid DNA Manufacturing Market, by Disease, 2021-2030

9.1.1. Infectious Disease

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Genetic Disorder

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Cancer

9.1.3.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.3. Market Revenue and Forecast, by Disease (2019-2030)

10.1.4. U.S.

10.1.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.1.5. Rest of North America

10.1.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.1.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.4. UK

10.2.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.5. Germany

10.2.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.6. France

10.2.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.6.3. Market Revenue and Forecast, by Disease (2019-2030)

10.2.7. Rest of Europe

10.2.7.1. Market Revenue and Forecast, by Product (2019-2030)

10.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

10.2.7.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.4. India

10.3.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.5. China

10.3.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.6. Japan

10.3.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.6.3. Market Revenue and Forecast, by Disease (2019-2030)

10.3.7. Rest of APAC

10.3.7.1. Market Revenue and Forecast, by Product (2019-2030)

10.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

10.3.7.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.4. GCC

10.4.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.5. North Africa

10.4.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.6. South Africa

10.4.6.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.6.3. Market Revenue and Forecast, by Disease (2019-2030)

10.4.7. Rest of MEA

10.4.7.1. Market Revenue and Forecast, by Product (2019-2030)

10.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

10.4.7.3. Market Revenue and Forecast, by Disease (2019-2030)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.3. Market Revenue and Forecast, by Disease (2019-2030)

10.5.4. Brazil

10.5.4.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.4.3. Market Revenue and Forecast, by Disease (2019-2030)

10.5.5. Rest of LATAM

10.5.5.1. Market Revenue and Forecast, by Product (2019-2030)

10.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

10.5.5.3. Market Revenue and Forecast, by Disease (2019-2030)

Chapter 11. Company Profiles

11.1. VGXI, Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Akron Biotech

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Cobra Biologics & Pharmaceutical Services

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Aldevron

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Plasmidfactory GmbH

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Vigene Biosciences

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Luminous Biosciences

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Nature Technology Corporation

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Delphi Genetics

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. JAFRAL Ltd.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Request for Customize Reports
Precedence offers custom market research services that help clients to get information on their business scenario required.

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence client

Get a Sample